MSNZ-P2 Dresden in the news

Cancer medicine is one of the most innovative segments of medicine. This progress is based on the results of clinician and medical scientists. It is however increasingly difficult for doctors to combine clinical duties with work in the laboratory. The difficulties faced by clinician scientists, and the resulting innovation backlog in medicine, are now increasingly being discussed by the public. 

The Mildred Scheel Early Career Centre Dresden P² provides support for doctors and medical researchers to accelerate their experimental work. Two of the funded fellows recently introduced themselves at the “Deutsche Krebskongress (DKK)” and in press interviews.

The research group of Dr. Anke Fuchs investigates novel cellular therapies to treat secondary diseases after haematopoietic stem cell transplantation. Dr. Cornelia Link-Rachners group explores changes in the immune cell repertoire of a cancer patient during the course of the disease with the intention of establishing predictable markers for cancer progression. In their interviews, they explain the advantages of being an MSNZ fellow and the extent to which their research projects enable innovative cancer therapies.

The Interviews

Dr. Anke Fuchs Interview on behalf of the 34. Deutsche Krebskongress 

Dr. Cornelia Link-Rachner Frankfurter Allgemeine Zeitung Verlagsspezial